Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

Using Signos mHealth Platform in Adults for Weight Management

NCT06214221 · View on ClinicalTrials.gov ↗

Study Summary

Metabolic syndrome and resulting downstream health effects remains a growing health concern. In published trials, the use of continuous glucose monitoring (CGM) assists behavioral changes efforts, leading to improved adherence and results from diet and exercise changes in individuals with obesity. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools that help participants in the pursuit of weight change goals. The investigators hypothesize that the use of CGM data and targeted coaching and nutrition education will assist with weight optimization goals in the general (non-diabetic) population using the Signos mHealth platform, with associated health benefits.

Interventions

  • DEVICE Signos System
  • OTHER Standard Lifestyle Education

Study Locations (5)

Arizona

  • Helios Clinical Research (Phoenix) — Phoenix

California

  • Diablo Clinical Research — Walnut Creek

Florida

  • Segal Trials — North Miami

Texas

  • Helios Clinical Research — Houston

Washington

  • Seattle Clinical Research — Seattle

Trial Details

FieldValue
Enrollment Target 380 participants
Start Date 2024-01-02
Est. Completion 2026-04-30
Phase NA

Sponsor

Signos

3 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06214221

The ClinicalTrials.gov registry entry for NCT06214221 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Signos, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Weight Loss appearing as the primary indexed condition, and to 2 interventions — of which Signos System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06214221 reports 5 study locations spanning 5 distinct geographic areas — top geographies include Arizona, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06214221 about?

NCT06214221 is a clinical study titled "Using Signos mHealth Platform in Adults for Weight Management". Metabolic syndrome and resulting downstream health effects remains a growing health concern. In published trials, the use of continuous glucose monitoring (CGM) assists behavioral changes efforts, leading to improved adherence and results from diet and exercise changes in individuals with obesity. M...

What is the current status of trial NCT06214221?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 380 participants. The study started on 2024-01-02. Estimated completion is 2026-04-30.

What conditions does trial NCT06214221 study?

This clinical trial studies the following conditions: Weight Loss, Overweight and Obesity, Metabolic Syndrome. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06214221?

The interventions under investigation include: Signos System (DEVICE), Standard Lifestyle Education (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06214221?

This trial is sponsored by Signos, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06214221 being conducted?

This trial has 5 study locations across Arizona, California, Florida, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial